Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2004 1
2006 1
2008 1
2012 1
2013 3
2016 1
2019 1
2020 5
2021 3
2022 8
2023 6
2024 6
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Did you mean E. S. E. sajjad (73 results)?
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.
Ivanova M, Porta FM, D'Ercole M, Pescia C, Sajjadi E, Cursano G, De Camilli E, Pala O, Mazzarol G, Venetis K, Guerini-Rocco E, Curigliano G, Viale G, Fusco N. Ivanova M, et al. Virchows Arch. 2024 Jan;484(1):3-14. doi: 10.1007/s00428-023-03656-w. Epub 2023 Sep 28. Virchows Arch. 2024. PMID: 37770765 Free PMC article. Review.
The trial focused on patients with metastatic breast cancer who were classified as "HER2-low," i.e., those with immunohistochemistry (IHC) HER2 1 + or 2 + and negative in situ hybridization (ISH) results. ...However, HER2-low offers a distinctive biomarker status that iden …
The trial focused on patients with metastatic breast cancer who were classified as "HER2-low," i.e., those with immunohistochemistry …
LATE-NC staging in routine neuropathologic diagnosis: an update.
Nelson PT, Lee EB, Cykowski MD, Alafuzoff I, Arfanakis K, Attems J, Brayne C, Corrada MM, Dugger BN, Flanagan ME, Ghetti B, Grinberg LT, Grossman M, Grothe MJ, Halliday GM, Hasegawa M, Hokkanen SRK, Hunter S, Jellinger K, Kawas CH, Keene CD, Kouri N, Kovacs GG, Leverenz JB, Latimer CS, Mackenzie IR, Mao Q, McAleese KE, Merrick R, Montine TJ, Murray ME, Myllykangas L, Nag S, Neltner JH, Newell KL, Rissman RA, Saito Y, Sajjadi SA, Schwetye KE, Teich AF, Thal DR, Tomé SO, Troncoso JC, Wang SJ, White CL 3rd, Wisniewski T, Yang HS, Schneider JA, Dickson DW, Neumann M. Nelson PT, et al. Acta Neuropathol. 2023 Feb;145(2):159-173. doi: 10.1007/s00401-022-02524-2. Epub 2022 Dec 13. Acta Neuropathol. 2023. PMID: 36512061 Free PMC article.
We provide practical suggestions about how to integrate available genetic information and comorbid pathologies [e.g., Alzheimer's disease neuropathologic changes (ADNC) and Lewy body disease]. We also describe recent research findings that have enabled more precise …
We provide practical suggestions about how to integrate available genetic information and comorbid pathologies [e.g., Alzheimer's …
Pure LATE-NC: Frequency, clinical impact, and the importance of considering APOE genotype when assessing this and other subtypes of non-Alzheimer's pathologies.
Katsumata Y, Wu X, Aung KZ, Fardo DW, Woodworth DC, Sajjadi SA, Tomé SO, Thal DR, Troncoso JC, Chang K, Mock C, Nelson PT. Katsumata Y, et al. Acta Neuropathol. 2024 Nov 15;148(1):66. doi: 10.1007/s00401-024-02821-y. Acta Neuropathol. 2024. PMID: 39546031 Free PMC article.
Pure limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes (pure LATE-NC) is a term used to describe brains with LATE-NC but lacking intermediate or severe levels of Alzheimer's disease neuropathologic changes (ADNC). Focusing on pure LATE-NC, we ana …
Pure limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes (pure LATE-NC) is a term used to describe brains with LATE …
The molecular landscape of breast mucoepidermoid carcinoma.
Venetis K, Sajjadi E, Ivanova M, Andaloro S, Pessina S, Zanetti C, Ranghiero A, Citelli G, Rossi C, Lucioni M, Malapelle U, Pagni F, Barberis M, Guerini-Rocco E, Viale G, Fusco N. Venetis K, et al. Cancer Med. 2023 May;12(9):10725-10737. doi: 10.1002/cam4.5754. Epub 2023 Mar 14. Cancer Med. 2023. PMID: 36916425 Free PMC article.
Developmental expression and distinctive tyrosine phosphorylation of the Eph-related receptor tyrosine kinase Cek9.
Soans C, Holash JA, Pavlova Y, Pasquale EB. Soans C, et al. J Cell Biol. 1996 Nov;135(3):781-95. doi: 10.1083/jcb.135.3.781. J Cell Biol. 1996. PMID: 8909550 Free PMC article.
Cek9 is a receptor tyrosine kinase of the Eph subfamily for which only a partial cDNA sequence was known (Sajjadi, F.G., and E.B. Pasquale. 1993. Oncogene. 8:1807-1813). We have obtained the entire cDNA sequence and identified a variant form of Cek9 that lacks a sig …
Cek9 is a receptor tyrosine kinase of the Eph subfamily for which only a partial cDNA sequence was known (Sajjadi, F.G., and E …
Associations of glycaemia-related risk factors with dementia and cognitive decline in individuals with type 2 diabetes: A systematic review and meta-analysis.
Tabesh M, Sacre JW, Mehta K, Chen L, Sajjadi SF, Magliano DJ, Shaw JE. Tabesh M, et al. Diabet Med. 2025 Oct;42(10):e70123. doi: 10.1111/dme.70123. Epub 2025 Aug 19. Diabet Med. 2025. PMID: 40828960 Free PMC article.
METHODS: We systematically searched Embase and MEDLINE (January 2000-October 2024) for studies in people with diabetes reporting longitudinal associations of a relevant exposure (i.e. hypoglycaemia, HbA1c, HbA1c variability or diabetes duration) with any of these outcomes: …
METHODS: We systematically searched Embase and MEDLINE (January 2000-October 2024) for studies in people with diabetes reporting longitudina …
The utility of recruitment incentives in early Alzheimer's disease trials.
Ritchie M, Witbracht M, Russ E, Sajjadi SA, Thai GT, Tam S, Gillen DL, Grill JD. Ritchie M, et al. Alzheimers Dement. 2024 Sep;20(9):6654-6658. doi: 10.1002/alz.14143. Epub 2024 Jul 27. Alzheimers Dement. 2024. PMID: 39072914 Free PMC article.
INTRODUCTION: Amid recent approvals, early Alzheimer's disease (AD) remains an active area of treatment development. METHODS: We performed a conjoint experiment to compare preferences among 26 patients with mild cognitive impairment for four trial features including design …
INTRODUCTION: Amid recent approvals, early Alzheimer's disease (AD) remains an active area of treatment development. METHODS: We perf …
Predicting the Macronutrient Composition of Mixed Meals From Dietary Biomarkers in Blood.
Das A, Mortazavi B, Sajjadi S, Chaspari T, Ruebush LE, Deutz NE, Cote GL, Gutierrez-Osuna R. Das A, et al. IEEE J Biomed Health Inform. 2022 Jun;26(6):2726-2736. doi: 10.1109/JBHI.2021.3134193. Epub 2022 Jun 3. IEEE J Biomed Health Inform. 2022. PMID: 34882568
In prior work, we showed that continuous glucose monitors (CGMs) may be used to predict meal macronutrients (e.g., carbohydrates, protein, fat) by analyzing the shape of the post-prandial glucose response. ...
In prior work, we showed that continuous glucose monitors (CGMs) may be used to predict meal macronutrients (e.g., carbohydrates, pro …
35 results